Dr. Catherine Vignal-Clermont
Rothschild Foundation Hospital, Paris
Ophthalmologist in the Department of Neuro-Ophthalmology and Emergencies at the Rothschild Foundation Hospital in Paris. Principal Investigator of the REVISE trial — a Phase 2 study evaluating lenadogene nolparvovec in patients with LHON — expected to begin in January 2026. Part of the original RESCUE/REVERSE trials team that established gene therapy efficacy in LHON.
Research focus
Public profiles
- Institution: https://www.fo-rothschild.fr/en
Contact is made via official institutional channels, not private email. To request removal, email the project.
Recent publications
-
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy
Science Translational Medicine · 2020
-
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset
Ophthalmology · 2021
Dr. Vignal-Clermont’s upcoming role as PI of the REVISE trial (2026) positions her as a key contact for anyone tracking the next phase of LHON gene therapy research. The trial will test lenadogene nolparvovec (LUMEVOQ) in patients not covered by previous studies.
Contact via the Rothschild Foundation Hospital Department of Neuro-Ophthalmology.
Project outreach status
Not yet contacted
Profile last verified: 2026-04-19